Literature DB >> 13572765

Soframycin: its penetration into the eye and its effect upon experimentally produced Staph. aureus and Ps. pyocyanea corneal infections.

D AINSLIE, W G HENDERSON.   

Abstract

Entities:  

Keywords:  ANTIBIOTICS/effects; CORNEA/diseases; EYE; MICROCOCCAL INFECTIONS/experimental; PSEUDOMONAS INFECTIONS/experimental

Mesh:

Substances:

Year:  1958        PMID: 13572765      PMCID: PMC509695          DOI: 10.1136/bjo.42.9.513

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


× No keyword cloud information.
  4 in total

1.  [Degrees of sensitivity and resistance of bacilli of the genuses Proteus and Providence to some antibiotics].

Authors:  A LUTZ; M J HOFFERER
Journal:  Rev Immunol Ther Antimicrob       Date:  1955

2.  Distribution of penicillin in the eye after injections of 1,000,000 units by the subconjunctival, retrobulbar and intramuscular routes.

Authors:  A SORSBY; J UNGAR
Journal:  Br J Ophthalmol       Date:  1948-12       Impact factor: 4.638

3.  Some problems in the tritration of streptomycin.

Authors:  J R MAY; A E VOUREKA; A FLEMING
Journal:  Br Med J       Date:  1947-05-10

4.  Polymyxin E, penetration into the eye and therapeutic value in experimental infection due to Ps. pyocyanea.

Authors:  D AINSLIE; C SMITH
Journal:  Br J Ophthalmol       Date:  1952-07       Impact factor: 4.638

  4 in total
  3 in total

1.  METHOD FOR THE PRESERVATION AND STERILIZATION OF FRESH DONOR MATERIAL FOR FULL-THICKNESS KERATOPLASTY BY GRAMYCETIN.

Authors:  P RYCROFT
Journal:  Br J Ophthalmol       Date:  1965-05       Impact factor: 4.638

2.  Subconjunctival administration of soframycin in the treatment of corneal infections.

Authors:  D AINSLIE; J E CARINS
Journal:  Br J Ophthalmol       Date:  1960-01       Impact factor: 4.638

3.  A study of aqueous and serum levels of ceftazidime following subconjunctival administration.

Authors:  D B Clements; V Tailor
Journal:  Br J Ophthalmol       Date:  1987-06       Impact factor: 4.638

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.